This post is also available in:
English
JoinAStudy.ca Investigator Dr. Anil Gupta was recently asked to assist in the presentation of strategies for preventing COVID progression and transmission in the outpatient setting, including the latest therapeutic developments. This effort was supported by an educational grant from Merck Sharp & Dohme Corp.
The presentation linked below will define the sub-populations that are most at risk of contracting COVID-19, identify those most at risk of a poor prognosis who may require earlier therapeutic intervention to prevent disease progression, and summarize clinical data for emerging/established therapies for preventing COVID-19 progression and/or transmission.
Dr Gupta has been at the forefront of COVID-19 research since the early stages of the pandemic, with his research leading to the Health Canada approval of sotrovimab, a drug found to reduce the likelihood of hospitalization in at-risk patients with COVID-19 by 85%. His research has also been published in the New England Journal of Medicine, a story that we covered and you can read more about here.